Advertisement

Künftige Entwicklung der Psychopharmakotherapie

  • F. Müller-Spahn

Zusammenfassung

Die Psychopharmakologie gilt heute als ein eigenständiger Forschungsbereich innerhalb der Neurowissenschaften. Unter der Bezeichnung Psychopharmaka werden eine Vielzahl unterschiedlicher Gruppen von Arzneimitteln zusammengefasst, die zur Behandlung psychischer Störungen dienen. Dazu zählen Anti- psychotika, Antidepressiva, Tranquilizer und Hypnotika, Psychostimulanzien sowie Nootropika bzw. Antidementiva. Pflanzliche Präparate (Phytopharmaka), wie das antidepressiv wirksame Johanniskraut, erfreuen sich zunehmender Beliebtheit. Dieser Beitrag versucht, in der gebotenen Kürze, streiflichtartig die wichtigsten aktuellen und zukünftigen Entwicklungen in der Psychopharmakologie störungsbezogen darzustellen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ator N and Kautz M (2000) Differentiating benzodiazepine and — barbiturate — like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil and zaleplon in two-versus three-lever procedures. Behavioural Pharmacology 11: 1–14PubMedCrossRefGoogle Scholar
  2. 2.
    Busto U, Naranjo C, Bremner K, Peachey J, Bologa M (1998) Safety of ipsapirone treatment compared with lorazepam: discontinuation effects. J Psychiatry Neurosci 23: 35–44PubMedGoogle Scholar
  3. 3.
    Dautzenberg F, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick G, Jenck F (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/noci-ceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. The Journal of Pharmacology and Experimental Therapeutics 298: 812–819PubMedGoogle Scholar
  4. 4.
    DeVane C (2000) Pharmacologic characteristics of ideal antidepressants in the 21st century. J Clin Psychiatry 61(Suppl 11): 4–8PubMedGoogle Scholar
  5. 5.
    Helmuth L (2000) An antibiotic to treat Alzheimer’s. Science 290: 1273–1274PubMedCrossRefGoogle Scholar
  6. 6.
    Hirai S (2000) Alzheimer Disease: current therapy and future therapeutic strategies. Alzheimer Disease and Associated Disorders 14(Suppl 1): 11–17CrossRefGoogle Scholar
  7. 7.
    Marx J (2001) New leads on the, how’ of Alzheimer’s. Science 293: 2192–2194PubMedCrossRefGoogle Scholar
  8. 8.
    Morrow B, Elsworth J, Lee E, Roth R (2000) Divergent effects of putative anxiolytics on stress-induced Fos expression in the mesoprefrontal system of the rat. Synapse 36: 143–154PubMedCrossRefGoogle Scholar
  9. 9.
    Müller-Spahn F (1999) Psychopharmaka. Therapeutische Umschau 56: 719–725PubMedCrossRefGoogle Scholar
  10. 10.
    Pacher P, Kohegyi E, Kecskemeti V, Furst S (2001) Current trends in the development of new antidepressants. Current Medical Chemistry 8: 89–100CrossRefGoogle Scholar
  11. 11.
    Revel L, Mennuni L, Garofalo P, Makovec F (1998) CR 2945: a novel CCKb receptor antagonist with anxiolytic-like activity. Behavioural Pharmacology 9: 183–194PubMedGoogle Scholar
  12. 12.
    Scatton B and Sanger D (2000) Pharmacological and molecular targets in the search for novel antipsychotics. Behavioural Pharmacology 11: 243–256PubMedCrossRefGoogle Scholar
  13. 13.
    Schenk D, Barbour R, Dunn W, Gordon G et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease like pathology in the PDAPP mouse. Nature 400: 173–177PubMedCrossRefGoogle Scholar
  14. 14.
    Skutella T, Probst J, Renner U, Holsboer F, Behl C (1998) Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 85: 95–805CrossRefGoogle Scholar
  15. 15.
    Tallman J (2000) Development of novel antipsychotic drugs. Brain Research Reviews 31: 385–390PubMedCrossRefGoogle Scholar
  16. 16.
    Wilkinson D (2001) Drugs for treatment of Alzheimer’s disease. Int J Clin Pract 55(2): 129–134PubMedGoogle Scholar
  17. 17.
    Winkler D und Jucker M (2001) Schon gegen Alzheimer geimpft? — Mechanismen zerebraler Amyloidosen. Schweiz Med Forum 28: 745–749Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • F. Müller-Spahn

There are no affiliations available

Personalised recommendations